1.17
1.17 (0%)
As of Feb 14, 2025
Sangamo Therapeutics, Inc [SGMO]
Source:
Company Overview
Sangamo Therapeutics, Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases.
| Country | United States |
| Headquarters | richmond, california |
| Phone Number | (510) 970-6000 |
| Industry | manufacturing |
| CEO | Alexander D. Macrae |
| Website | www.sangamo.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $57.8 |
| Operating Profit | $-104 |
| Net Income | $-97.9 |
| Net Cash | $-3.3 |
Profit Ratios
| Gross Margin | $57.8 |
| Operating Margin | -179.9 |
| Profit as % of Revenues | -59% |
| Profit as % of Assets | -73.4% |
| Profit as % of Stockholder Equity | -430.1% |
Management Effectiveness
| Return on Equity | -430.1% |
| Return on Assets | -96.4% |
| Turnover Ratio | 43.3% |
| EBITA | $-104 |
Balance Sheet and Cash Flow Measures
| Total Assets | $101.6 |
| Total Liabilities | $78.9 |
| Operating Cash Flow | $-67.1 |
| Investing Cash Flow | $37.5 |
| Financing Cash Flow | $28.4 |
